Skip to main content

Inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis (iABC)


The library consists of iABC related publications, posters, presentations, and press releases

Poster ERS 2018
Multiple Breath Washout (MBW) training, certification and quality control during the iBEST 1 trial in bronchiectasis (BE).

  The EMBARC European Bronchiectasis Registry Protocol
Bronchiectasis is one of the most neglected diseases in respiratory medicine. There are no approved therapies and few large-scale, representative epidemiological studies.

Cross-infection risk in patients with bronchiectasis
a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network

Patient participation in ERS guidelines and research projects
The EMBARC experience

iBest 1 poster (2017)
Dose-finding study to assess the efficacy, safety and tolerability of tobramycin inhalation powder in patients with non-cystic fibrosis bronchiectasis and pulmonary Pseudomonas aeruginosa infection (iBEST-1)

Use of Calgary and microfluidic BioFlux systems
To test the activity of fosfomycin and tobramycin alone and in combination against cystic fibrosis Pseudomonas
aeruginosa biofilms

  Design of the iBest study
Efficacy and safety of tobramycin inhalation powder in bronchiectasis patients with P. aeruginosa infection: Design of a dose-finding study (iBEST-1)